Literature DB >> 25313323

Crystal Structures and Structure-Activity Relationships of Imidazothiazole Derivatives as IDO1 Inhibitors.

Shingo Tojo1, Tetsuya Kohno1, Tomoyuki Tanaka1, Seiji Kamioka1, Yosuke Ota1, Takayuki Ishii1, Keiko Kamimoto1, Shigehiro Asano1, Yoshiaki Isobe1.   

Abstract

Indoleamine 2,3-dioxygenase 1 (IDO1) is considered as a promising target for the treatment of several diseases, including neurological disorders and cancer. We report here the crystal structures of two IDO1/IDO1 inhibitor complexes, one of which shows that Amg-1 is directly bound to the heme iron of IDO1 with a clear induced fit. We also describe the identification and preliminary optimization of imidazothiazole derivatives as novel IDO1 inhibitors. Using our crystal structure information and structure-activity relationships (SAR) at the pocket-B of IDO1, we found a series of urea derivatives as potent IDO1 inhibitors and revealed that generation of an induced fit and the resulting interaction with Phe226 and Arg231 are essential for potent IDO1 inhibitory activity. The results of this study are very valuable for understanding the mechanism of IDO1 activation, which is very important for structure-based drug design (SBDD) to discover potent IDO1 inhibitors.

Entities:  

Keywords:  Indoleamine 2,3-dioxygenagse 1; crystal structure; imidazothiazole; induced fit; structure-based drug discovery

Year:  2014        PMID: 25313323      PMCID: PMC4190630          DOI: 10.1021/ml500247w

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  16 in total

1.  High-level production of heme-containing holoproteins in Escherichia coli.

Authors:  Y Jung; J Kwak; Y Lee
Journal:  Appl Microbiol Biotechnol       Date:  2001-03       Impact factor: 4.813

2.  Purification and kinetic characterization of human indoleamine 2,3-dioxygenases 1 and 2 (IDO1 and IDO2) and discovery of selective IDO1 inhibitors.

Authors:  David Meininger; Leeanne Zalameda; Yichin Liu; Lara P Stepan; Luis Borges; John D McCarter; Claire L Sutherland
Journal:  Biochim Biophys Acta       Date:  2011-07-31

Review 3.  Indoleamine 2,3-dioxygenase expression in human cancers: clinical and immunologic perspectives.

Authors:  Jessica Godin-Ethier; Laïla-Aïcha Hanafi; Ciriaco A Piccirillo; Réjean Lapointe
Journal:  Clin Cancer Res       Date:  2011-11-08       Impact factor: 12.531

Review 4.  Biochemical and medical aspects of the indoleamine 2,3-dioxygenase-initiated L-tryptophan metabolism.

Authors:  Osamu Takikawa
Journal:  Biochem Biophys Res Commun       Date:  2005-09-15       Impact factor: 3.575

5.  Molecular insights into substrate recognition and catalysis by tryptophan 2,3-dioxygenase.

Authors:  Farhad Forouhar; J L Ross Anderson; Christopher G Mowat; Sergey M Vorobiev; Arif Hussain; Mariam Abashidze; Chiara Bruckmann; Sarah J Thackray; Jayaraman Seetharaman; Todd Tucker; Rong Xiao; Li-Chung Ma; Li Zhao; Thomas B Acton; Gaetano T Montelione; Stephen K Chapman; Liang Tong
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-29       Impact factor: 11.205

Review 6.  Kynurenines in the CNS: recent advances and new questions.

Authors:  László Vécsei; Levente Szalárdy; Ferenc Fülöp; József Toldi
Journal:  Nat Rev Drug Discov       Date:  2012-12-14       Impact factor: 84.694

Review 7.  Indoleamine 2,3-dioxygenase and tumor-induced tolerance.

Authors:  David H Munn; Andrew L Mellor
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

8.  Structure based development of phenylimidazole-derived inhibitors of indoleamine 2,3-dioxygenase.

Authors:  Sanjeev Kumar; Daniel Jaller; Bhumika Patel; Judith M LaLonde; James B DuHadaway; William P Malachowski; George C Prendergast; Alexander J Muller
Journal:  J Med Chem       Date:  2008-07-30       Impact factor: 7.446

9.  1-Methyl-DL-tryptophan, beta-(3-benzofuranyl)-DL-alanine (the oxygen analog of tryptophan), and beta-[3-benzo(b)thienyl]-DL-alanine (the sulfur analog of tryptophan) are competitive inhibitors for indoleamine 2,3-dioxygenase.

Authors:  S G Cady; M Sono
Journal:  Arch Biochem Biophys       Date:  1991-12       Impact factor: 4.013

10.  Crystal structure of human indoleamine 2,3-dioxygenase: catalytic mechanism of O2 incorporation by a heme-containing dioxygenase.

Authors:  Hiroshi Sugimoto; Shun-ichiro Oda; Takashi Otsuki; Tomoya Hino; Tadashi Yoshida; Yoshitsugu Shiro
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-13       Impact factor: 11.205

View more
  30 in total

1.  Aminoisoxazoles as Potent Inhibitors of Tryptophan 2,3-Dioxygenase 2 (TDO2).

Authors:  Zhonghua Pei; Rohan Mendonca; Lewis Gazzard; Richard Pastor; Leanne Goon; Amy Gustafson; Erica VanderPorten; Georgia Hatzivassiliou; Kevin Dement; Robert Cass; Po-Wai Yuen; Yamin Zhang; Guosheng Wu; Xingyu Lin; Yichin Liu; Benjamin D Sellers
Journal:  ACS Med Chem Lett       Date:  2018-04-02       Impact factor: 4.345

2.  Diaryl hydroxylamines as pan or dual inhibitors of indoleamine 2,3-dioxygenase-1, indoleamine 2,3-dioxygenase-2 and tryptophan dioxygenase.

Authors:  Maria Winters; James B DuHadaway; Khoa N Pham; Ariel Lewis-Ballester; Shorouk Badir; Jenny Wai; Eesha Sheikh; Syun-Ru Yeh; George C Prendergast; Alexander J Muller; William P Malachowski
Journal:  Eur J Med Chem       Date:  2018-11-14       Impact factor: 6.514

3.  Discovery of indoleamine 2,3-dioxygenase inhibitors using machine learning based virtual screening.

Authors:  Hongao Zhang; Wei Liu; Zhihong Liu; Yingchen Ju; Mengyang Xu; Yue Zhang; Xinyu Wu; Qiong Gu; Zhong Wang; Jun Xu
Journal:  Medchemcomm       Date:  2018-03-01       Impact factor: 3.597

4.  O-alkylhydroxylamines as rationally-designed mechanism-based inhibitors of indoleamine 2,3-dioxygenase-1.

Authors:  William P Malachowski; Maria Winters; James B DuHadaway; Ariel Lewis-Ballester; Shorouk Badir; Jenny Wai; Maisha Rahman; Eesha Sheikh; Judith M LaLonde; Syun-Ru Yeh; George C Prendergast; Alexander J Muller
Journal:  Eur J Med Chem       Date:  2015-12-17       Impact factor: 6.514

Review 5.  Recent advances in the discovery of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.

Authors:  Xiu-Xiu Wang; Si-Yu Sun; Qing-Qing Dong; Xiao-Xiang Wu; Wei Tang; Ya-Qun Xing
Journal:  Medchemcomm       Date:  2019-08-15       Impact factor: 3.597

6.  Structural Basis of Inhibitor Selectivity in Human Indoleamine 2,3-Dioxygenase 1 and Tryptophan Dioxygenase.

Authors:  Khoa N Pham; Ariel Lewis-Ballester; Syun-Ru Yeh
Journal:  J Am Chem Soc       Date:  2019-11-14       Impact factor: 15.419

7.  Fused Heterocyclic Compounds as Potent Indoleamine-2,3-dioxygenase 1 Inhibitors.

Authors:  Subhankar Panda; Ashalata Roy; Suman Jyoti Deka; Vishal Trivedi; Debasis Manna
Journal:  ACS Med Chem Lett       Date:  2016-10-15       Impact factor: 4.345

8.  Identification of Potent Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors Based on a Phenylimidazole Scaffold.

Authors:  Michael G Brant; Jake Goodwin-Tindall; Kurt R Stover; Paul M Stafford; Fan Wu; Autumn R Meek; Paolo Schiavini; Stephanie Wohnig; Donald F Weaver
Journal:  ACS Med Chem Lett       Date:  2018-01-11       Impact factor: 4.345

9.  Mapping the Binding Trajectory of a Suicide Inhibitor in Human Indoleamine 2,3-Dioxygenase 1.

Authors:  Khoa N Pham; Syun-Ru Yeh
Journal:  J Am Chem Soc       Date:  2018-10-24       Impact factor: 15.419

10.  Structural Study of a Flexible Active Site Loop in Human Indoleamine 2,3-Dioxygenase and Its Functional Implications.

Authors:  Lucía Álvarez; Ariel Lewis-Ballester; Adrián Roitberg; Darío A Estrin; Syun-Ru Yeh; Marcelo A Marti; Luciana Capece
Journal:  Biochemistry       Date:  2016-05-06       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.